Welcome to our dedicated page for Entera Bio Ltd. SEC filings (Ticker: ENTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Entera Bio Ltd. filings document a Nasdaq-listed Israeli clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies. Its recent Form 8-K disclosures cover financial results, Regulation FD updates, EB613 regulatory and clinical-development communications, and business updates across oral peptide programs.
The filing record also documents material agreements and capital structure matters, including collaboration and license arrangements with OPKO, a private placement involving ordinary shares, pre-funded warrants and ordinary share warrants, and governance disclosures related to board appointments. These filings frame ENTX's operating updates, securities structure, partnership obligations and public-company governance.
Entera Bio Ltd. received a beneficial ownership report from TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC and Chen Yu. The reporting persons disclose beneficial ownership of 12,254,901 ordinary shares of Entera Bio, representing 7.1% of the outstanding ordinary shares, with shared voting and dispositive power over all such shares and no sole voting or dispositive power. The ownership percentage is calculated based on 172,251,449 ordinary shares outstanding, comprising 49,290,234 ordinary shares outstanding as of May 19, 2026 and 122,961,215 ordinary shares issued in a private placement that closed on July 28, 2026. The securities are held of record by TCG Crossover Fund III, L.P., for which TCG Crossover GP III serves as general partner; Chen Yu is the sole managing member of TCG Crossover GP III. Each reporting person disclaims beneficial ownership except to the extent of its or his pecuniary interest.
Entera Bio Ltd. has a new large shareholder group led by Vivo Opportunity entities. Vivo Opportunity, LLC may be deemed to beneficially own 11,817,401 Ordinary Shares, representing 6.9% of Entera Bio’s Ordinary Shares outstanding. These shares are held through Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Co-Invest, L.P., and Vivo Opportunity Co-Invest (Cycle 3), L.P.
Vivo Opportunity Cayman, LLC may be deemed to beneficially own an additional 437,500 Ordinary Shares, or 0.3% of the class, held by Vivo Opportunity Cayman Fund, L.P. The ownership percentages are based on 172,251,411 Ordinary Shares outstanding, which includes 122,961,215 Ordinary Shares issued in a private placement completed on July 28, 2026. Each Vivo entity reports sole voting and dispositive power over its respective holdings.
Entera Bio Ltd. completed a private placement with institutional and accredited investors for 134,803,910 ordinary shares (or pre-funded warrants) at $2.04 per share, raising approximately $275.0 million. On July 28, 2026 it issued 122,961,215 ordinary shares and 11,842,695 pre-funded warrants.
The pre-funded warrants are immediately exercisable at an exercise price of NIS 0.0000769 per ordinary share, have no expiration date and include 4.99% or 9.99% beneficial ownership limits, with potential increases up to 19.99%. Net proceeds are intended to support initiation of a phase 3 registrational study of EB613 in postmenopausal women with osteoporosis and for general working capital and corporate purposes.
Funds affiliated with BVF Partners L.P. obtained rights to designate up to two directors, which step down at 75.0%, 50.0% and 10.0% ownership thresholds, and one designee is expected to serve on the Nominating and Governance Committee. Purchasers agreed to support proposals to increase the 2018 Equity Incentive Plan share reserve and approve executive equity grants restoring pre-transaction beneficial ownership levels. Entera Bio agreed to file a resale registration statement within 30 days of closing and to use reasonable best efforts to have it declared effective.
Entera Bio Ltd. held its 2026 Annual Meeting of Shareholders on July 14, 2026. Shareholders approved an amendment to the 2018 Equity Incentive Plan adding a one-time 2,500,000 Ordinary Shares to the pool available for equity awards. They also approved an Articles Amendment increasing authorized Ordinary Shares from 140,010,000 to 350,000,000.
Shareholders re-elected Sean Ellis, Steven D. Rubin and Geno H. Germano as Class III directors for terms running until the 2029 Annual Meeting. They approved revised non-executive director compensation, several one-time and share-based compensation grants, an advisory say-on-pay proposal, and the appointment of Kesselman & Kesselman as independent auditors for the fiscal year ending December 31, 2026.
Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. reported that CEO Toledano Miranda Jayne received two grants of stock-settled restricted stock units representing 72,993 and 347,567 ordinary shares on July 14, 2026. The awards were approved by the board on May 7, 2026 and by shareholders on July 14, 2026.
One grant was awarded in lieu of her 2025 annual cash bonus, and the other in lieu of $100,000 of her 2026 base salary. Both RSU grants vest ratably on a quarterly basis over a one-year period that began on May 1, 2026, with full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.
Entera Bio Ltd. has called its 2026 Annual Meeting of Shareholders for July 14, 2026 in Jerusalem. Shareholders of record as of May 19, 2026, when 49,290,234 ordinary shares were outstanding, may vote in person, by mail or via Internet under SEC “Notice and Access” rules.
Key votes include electing three Class III directors to terms ending in 2029, multiple director and executive compensation items, and an amendment to the 2018 Equity Incentive Plan to increase the number of shares issuable thereunder by 2,500,000 shares. Shareholders will also vote on increasing the Company’s authorized share capital, an advisory say‑on‑pay resolution, and ratification of Kesselman & Kesselman (PwC affiliate) as independent auditors for 2026.
The proxy details Israeli Companies Law requirements, including special majority provisions for certain compensation proposals and definitions of controlling shareholders and personal interests, and describes Entera Bio’s board structure, committee composition, corporate governance practices and major shareholders.
Entera Bio Ltd. registers for resale up to 19,569,472 ordinary shares comprised of 2,425,000 issued shares, up to 5,402,789 issuable upon exercise of Pre‑Funded Warrants and up to 11,741,683 issuable upon exercise of Ordinary Share Warrants from a Private Placement consummated on April 2, 2026. The resale registration is being made pursuant to a Registration Rights Agreement and the company will not receive proceeds from resale transactions; however, it may receive proceeds from any cash exercises of the Warrants. The prospectus states the company will pay registration fees and expenses and that offer methods and underwriter names, if any, will be specified in prospectus supplements.
Entera Bio Ltd. is soliciting proxies for its 2026 Annual Meeting of Shareholders to be held July 14, 2026, where shareholders will vote on ten proposals including the election of three Class III directors and amendments to its equity plans and authorized share capital.
The record date for voting is May 19, 2026. The meeting packet includes the Company’s audited consolidated financial statements for the year ended December 31, 2025, and the Proxy Materials are being furnished under the SEC "Notice and Access" model.